NTX-1955, also known as RO-7308480, is a selective γ1 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of generalized anxiety disorder. It is taken orally. Classical benzodiazepines are GABAA receptor positive allosteric modulators that act mainly upon γ2 subunit-containing GABAA receptors. GABAA receptor γ2 subunits are the most abundantly expressed GABAA receptor subunits in the brain and are present in at least 90% of all GABAA receptors in the forebrain. Moreover, they show high expression in the amygdala and have been extensively implicated in suppressing anxiety via actions in this area. Conversely, NTX-1955 is a selective positive allosteric modulator of γ1 subunit-containing GABAA receptors. Though γ2 subunit-containing GABAA receptors are dominant in this area, γ1 subunit-containing GABAA receptors are also highly expressed in the central amygdala, and selective positive allosteric modulators of these receptors have been found to produce anxiolytic-like effects without side effects like sedation and cognitive and motor impairment in animals. As such, it is thought that selectivity for γ1 subunit-containing GABAA receptors may confer improved tolerability compared to existing drugs like benzodiazepines. Due to its novel mechanism of action, NTX-1955 is a potential first-in-class medication. NTX-1955 was originated by Roche and is under development by Newleos Therapeutics. As of April 2026, it is in phase 1 clinical trials for generalized anxiety disorder, with several phase 1 trials having been completed. There was also interest in NTX-1955 for potential treatment of social anxiety disorder. The chemical structure of NTX-1955 does not yet appear to have been disclosed, but it is said to be structurally related to benzodiazepines.
See also List of investigational generalized anxiety disorder drugs ENX-102 (TPA-023B)
References
